Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Change in number of shares and votes in Immunovia AB (publ)

June 29, 2018

The number of shares in Immunovia AB (publ) has changed due to the issue of 2,162,794 shares resolved by the Board in June.

Following the registration of the new share issue with the Swedish Companies Registration Office and the introduction of the new shares in the share register held by Euroclear Sweden AB, the total number of shares and votes in Immunovia AB (publ) amounts to 19,480,853 shares. 

This is information that Immunovia is obliged to make public pursuant to the Swedish Act on Trade in Financial Instruments. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on June 29, 2018. 

For further information, please contact:
Mats Grahn
Chief Executive Officer, CEO, Immunovia
Tel.: +46-70-5320230

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source:

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit

Change in number of shares and votes in Immunovia AB (publ)